The GMP endonuclease for viral vector manufacturing
DENARASE® is a recombinantly produced endonuclease from Serratia marcescens. It is applied for the degradation of undesired DNA and RNA during the manufacturing of biopharmaceutical products – namely viral vectors.
Main areas of application
- Production of viral vectors for cell and gene therapies
- Production of vaccines
The enzyme cleaves all forms of DNA and RNA into smaller nucleotides of about 3-5 base pairs. This property is used in biopharmaceutical manufacturing to degrade all forms of undesired host and plasmid DNA. The degraded nucleotides can then be easily removed in the subsequent purification steps.
DENARASE® meets the most stringent regulatory and quality requirements for applications in biopharmaceutical production.
DENARASE® has a purity of ≥ 99% and is produced in full compliance with the EU GMP requirements. The enzyme is manufactured with raw materials of non-animal origin only and without the use of antibiotics. The patented production method makes use of Bacillus sp. as production strain. This gram-positive, endotoxin-free strain is highly productive and reduces the risk of endotoxins in the final product.
Learn more about DENARASE®
More information about the products, free samples and prices can be found here:
DENARASE® is a registered trademark of c-LEcta GmbH in the European Union (EU), United States of America (USA), United Kingdom (UK), China (CN), India (IN), South-Korea (KR) and Japan (JP).